Authors
Na Mo, Ming Wang, Qiong Jin, Tong Wang, Shuli Yang, Haili Kang, Chunyan He, Xingzheng Zheng, Pingping Zhong, Yang Zhan, Yumei Wu, Yulan Jin
Published in
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Pages 101116. Nov 12, 2026. Epub Nov 12, 2026.
Abstract
Pilomatrix-like high-grade endometrioid carcinoma (PiMHEC) is a rare endometrial neoplasm with incompletely defined diagnostic criteria and molecular pathogenesis. Clinicopathologic, immunohistochemical, and genomic features were analyzed in 15 PiMHEC cases: 14 uterine PiMHECs and 1 case with PiMHEC confined to an ovarian metastasis from a uterine low-grade endometrioid carcinoma (LGEC). All PiMHECs contained a dominant high-grade basaloid component (HGBC) with nested architecture and geographic necrosis; shadow cells were present in 12 of 15 cases. Concurrent LGEC (n=10) and atypical hyperplasia (n=6) were identified. The HGBC lacked ER, PR, and PAX8 expression, showed aberrant nuclear β-catenin accumulation, and expressed CD10 and CDX2 in all cases. CTNNB1 exon 3 mutations were detected in 13 cases; the remaining 2 CTNNB1-wildtype tumors harbored truncating APC mutations. PI3K/AKT pathway gene alterations were present in all cases and ARID1A alterations in 14 of 15 cases. Shared somatic mutations were identified in 4 paired HGBC and LGEC cases. Among 13 evaluable surgical specimens, metastases occurred with extensive lymphovascular space invasion (LVSI) in 60% (3/5), focal LVSI in 80% (4/5), and no LVSI in 33% (1/3). Outcomes differed by molecular subtype: 6/8 no specific molecular profile (NSMP) patients died within one year, whereas all seven deficient mismatch repair (dMMR) patients were alive at last follow-up. Two dMMR patients received immune checkpoint inhibitor (ICI)-containing regimens, with one durable response and one immune-mediated colitis-related discontinuation. These findings support PiMHEC derivation from an LGEC; the entity is characterized by Wnt/β-catenin pathway activation, with APC inactivation representing a potential novel alternative driver in CTNNB1-wildtype tumors. The differing outcomes between NSMP and dMMR tumors require cautious interpretation given the small cohort and ICI exposure in a subset of dMMR patients; nevertheless, ICI therapy warrants further evaluation in dMMR PiMHEC.
PMID:
43020431
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0